PASW News & Events

Ping An Biomedical Co. files to sell 13.61M ordinary shares for holders

Ping An Biomedical entered into a non-binding memorandum with Future Biotechnology Group. The Investment Memorandum outlines an initial investment of $30M to be paid in cash, as well as subsequent acquisitions with a consideration, in aggregate, of $60M to be settled in cash and share issuances. The Consideration Shares are to be held escrow and released in accordance with performance targets over an evaluation period of 3 years from January 2026 to December 2028.

Ping An Biomedical has entered into a series of share purchase agreements with several investors: Yao Jinbo, Chairman and CEO of 58 Group; Wang Donghui, Founder and Managing Partner of Amiba Capital; and Li Daxue, Chairman and CEO of Magcloud Group and former Senior Vice President of JD.com and its Lifetime Honorary Advisor.

Ping An Biomedical Co. announced receipt of Nasdaq Minimum Bid Price Deficiency Letter. On November 24, 2025, Ping An Biomedical Co. received a letter from the Listing Qualifications staff of The Nasdaq Stock Market notifying the company that based on the closing bid price of the company for the period from October 10, 2025 to November 20, 2025, the company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share. Nasdaq has provided the company with an 180 calendar days compliance period, or until May 25, 2026, in which to regain compliance with Nasdaq continued listing requirement.